BIAF Share Price Performance
US$4.00
-3.86 (-49.09%)
Price US$4.00
Share Pricen/a
bioAffinity Technologies, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
BIAF Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
bioAffinity Technologies, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -3.32
- 31.40%
- -241.96%
- 2.0%
About BIAF
- Founded
- 2014
- Employees
- 57
- CEO
- WebsiteView website
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
